Abstract: This invention encompasses a pharmaceutical composition comprising an effective amount of alendronate salt for reducing calcium loss and an effective amount of a gastric propulsive agent, preferably cisapride, to prevent gastric reflux caused by the alendronate salt.

Abstract: A drug delivery system useful in treating individuals having maladies requiring topical, subcutaneous and intra-lesional administration of one or more drugs for a prolonged period of time. A method for treating individuals with noduloulcerative carcinomas using the present invention drug delivery system and intra-lesional administration of interferon to the individual in a controlled, sustained release manner such that long-term therapeutic levels of interferon are provided to the individual. A method of treating an individual having certain skin infections using the present invention drug delivery system including topical and/or subcutaneous administration of one or more drugs to the individual in a controlled, sustained release manner such that long-term therapeutic levels of the drug(s) are provided to the individual.

Abstract: A method and kit for positioning a transdermal drug delivery system useful in treating individuals having maladies requiring topical, subcutaneous, intra-lesional and systemic administration of one or more drugs for a prolonged period of time is disclosed. A method for employing the present invention kit allows a patient to accurately self-administer a prolonged treatment regimen including a transdermal delivery system without the substantial involvement of medical personnel.

Abstract: The present invention is a method and a dosage unit for delivery of a controlled-release system. The dosage unit is a quick dissolve unit which can be prepared by mixing uncured shearform matrix and a controlled-release system, either molding or compacting a unit dosage form and curing the shearform matrix. The controlled-release systems used in the present invention include instantaneous release components, delayed release components, sustained release components, and combinations thereof.

Abstract: The present invention is a process for forming a low density compression dosage unit to provide increased strength. The process of the present invention includes compacting under bi-level compaction pressure to provide a continuous-volume dosage unit which has a first volume defining an edge portion of the unit and a density which is greater than a density of a second volume defining a non-edge portion of the unit. The present invention also includes the product resulting from the process and apparatus used to make such units.

Abstract: The invention deals with porous aggregates and a process for making same. The aggregates generally comprise discrete particles which are bound together, the aggregates having intra-aggregate volumes which may contain drug substances or other functional substances.

Abstract: Certain tetralinyl- and indanyl-ethylamides are useful central nervous system agents.

Abstract: New melatonergic agents are phenyl alkanyl or phenyl alkyl substituted carboxamides and ureas of Formula I: ##STR1## wherein: R.sub.1 =C.sub.1-3 alkyl, allyl, C.sub.3-6 cycloalkyl substituted C.sub.1-4 alkyl;R.sub.2 =hydrogen, halogen or C.sub.1-4 alkoxy;R.sub.3 =hydrogen or C.sub.1-4 alkyl;R.sub.4 =C.sub.1-4 alkyl, C.sub.1-4 alkyl substituted amino, carboxylic acid substitutedC.sub.1-4 alkyl or C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkyl, or straight or branched chainC.sub.2-4 alkenyl;A=a linear C.sub.2-4 alkanediyl or alkenediyl chain, provided that A not be --CH.sub.2 CH.sub.2 -- when X is a bond; andX=a covalent bond or oxygen.

Abstract: Certain aminomethyl-benzodioxanes and benzopyrans are useful serotonergic agents. They possess anxiolytic properties with few of the side effects often associated with dopaminergic agents.

Abstract: The present invention provides temperature stable crystalline etoposide 4'-phosphate diethanol solvate, and a process for its preparation.

Abstract: The present invention relates to novel antitumor depsipeptides produced by Micromonospora strain 39500, ATCC 55011, and having the structural formula ##STR1## wherein R.sub.1 is 2-methylpropanoyl, and R.sub.2 is 2-methylppropanoyl, propanoyl or acetyl; or R.sub.1 is 3-methylbutanoyl, and R.sub.2 is 2-methylpropanoyl or 3-methylbutanoyl; or R.sub.1 is propanoyl, and R.sub.2 is acetyl or propanoyl.

Abstract: Certain novel 1H-cycloundeca[1,2-b:5,6-b']biscyclohepta(b)pyran analogs are useful as antitumor agents.

Abstract: Certain N-acyl-cycloalkylamine derivatives are useful as melatonergic agents.

Abstract: Piperidinyl-substituted cyclohexanes of Formula I have anti-ischemic properties: ##STR1## wherein R=R.sub.1 and is independently H or halogen; or R and R.sub.1 may be taken together to form an --O(CH.sub.2).sub.m O-- (m=1 or 2);X=a phenyl residue;R.sub.2 =R.sub.3 and is independently H or C.sub.1-4 alkyl; andR.sub.4 =phenyl or substituted phenyl wherein the phenyl group is mono-, or di-substituted with groups selected from: F, Cl, I and C.sub.1-4 alkoxy.

Abstract: New melatonergic agents are phenyl alkanyl or phenyl alkyl substituted carboxamides and ureas of Formula I: ##STR1## wherein: R.sub.1 =C.sub.1-3 alkyl, allyl, C.sub.3-6 cycloalkyl substituted C.sub.1-4 alkyl;R.sub.2 =hydrogen, halogen or C.sub.1-4 alkoxy;R.sub.3 =hydrogen or C.sub.1-4 alkyl;R.sub.4 =C.sub.1-4 alkyl, C.sub.1-4 alkyl substituted amino, carboxylic acid substitutedC.sub.1-4 alkyl or C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkyl, or straight or branched chain C.sub.2-4 alkenyl;A=a linear C.sub.2-4 alkanediyl or alkenediyl chain, provided that A not be --CH.sub.2 CH.sub.2 -- when X is a bond; andX=a covalent bond or oxygen.

Abstract: Novel 3-alkoxybenzylpiperidines have melatonergic properties. They are believed useful in treating depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, some disorders associated with reproduction, cancer, immune disorders and neuroendocrine disorders.

Abstract: Stable parenteral antitumor formulations contain elsamitrucin salt, a stabilizer and a buffer. The formations are optionally stored in sealed containers under air or nitrogen headspace.

Abstract: New central nervous system agents conform to formula I: ##STR1## wherein R=H or C.sub.1-4 alkoxy;X=CH or N;Y=NH, O or S;Z=C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.2-3 alkenyl, NH.sub.2, C.sub.1-4 alkylamino, or C.sub.1-4 alkoxyalkyl, with the proviso that Z may not be CH.sub.3 when R=H, X=CH, and Y=NH and Z may not be CH.sub.3 when R=H, X=N and Y=NH and NHC(O)Z is in the para- position.

Abstract: Stable solutions of rebeccamycin analog consist essentially of (a) water, (b) 8-N-(diethylaminoethyl)rebeccamycin in an effective dosage amount, and (c) pharmaceutically acceptable acid such that the presence of a molar equivalence thereof would solubilize (b), said acid being present in excess of said molar equivalence to provide a stabilizing pH ranging from 3 to 4, preferably from 3.0 to 3.6. A preferred solution contains 10 mg/ml of the free base and tartaric acid in equimolar amount with the free base to provide a pH of 3.5. Preferably, the solution is prepared by forming a suspension of 8-N-(diethylaminoethyl)rebeccamycin in water and adding acid to provide a pH ranging from 3 to 4.

Abstract: Certain aminomethyl-benzodioxanes and benzopyrans are useful serotonergic agents. They possess anxiolytic properties with few of the side effects often associated with dopaminergic agents.